170482 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants; Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 CD28, CD152
PHARMACOKINETIC MODELING SYSTEMS FOR IMPROVED THERAPEUTIC DOSING
#2METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY
#3ANTI-HUMAN ICOS ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS AND FOR DIAGNOSING CANCER
#4METHODS AND PRODUCTS FOR DETERMINING RESPONSIVENESS TO ANTI-PD1 IMMUNE CHECKPOINT INHIBITOR IMMUNOTHERAPY
#5COMPOSITIONS AND METHODS FOR DETECTION OF METASTASIS
#6NEUTRALIZATION ANTIBODY ASSAY METHOD
#7METHODS FOR DETERMINING ONE OR MORE CRITICAL QUALITY ATTRIBUTES OF CO-FORMULATED ANTIBODIES
#8ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF
#9MULTI-DOMAIN MOLECULES
#10CTLA-4 Binding Molecule and Use Thereof
#11ANTI-BTLA ANTIBODIES AND USES THEREOF IN TREATING CANCER
#12Combination Of Proteotypic Peptides For The Detection Of Proteins In The Pd-L1 Axis
#13CLINICAL TIER GRADING FOR PROGNOSIS OF IMMUNE CHECKPOINT INHIBITOR EFFICACY AND CLINICAL STATUS
#14PREDICTIVE RESPONSE BIOMARKER DISCOVERY PROCESS
#15T CELL AND NK CELL ENGAGERS
#16METHODS AND SYSTEMS FOR PREDICTING RESPONSE TO PD-1 AXIS DIRECTED THERAPEUTICS IN COLORECTAL TUMORS WITH DEFICIENT MISMATCH REPAIR
#17CD28 BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
#18ANTI-PD-1 ANTIBODY AND USE THEREOF
#19ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF
#20METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
#21MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF
#22MEANS AND METHODS FOR ASSESSING IMMUNOTHERAPY
#23ANTI-CTLA4 AND ANTI-PD-1 BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
#24MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE
#25METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA
#26METHODS OF DIAGNOSING AND TREATING LUPUS
#27SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY
#28PREDICTIVE LIQUID MARKERS FOR CANCER IMMUNOTHERAPY
#29BIOMARKERS FOR DETERMINING THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS
#30PERIPHERAL BLOOD BIOMARKER FOR EVALUATING ANTI-TUMOR IMMUNE EFFECT OF RADIATION THERAPY
#31BISPECIFIC ANTIBODY AND USE THEREOF
#32DATA PROCESSING SYSTEM FOR IDENTIFYING A THERAPEUTIC AGENT
#33PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
#34METHODS RELATED TO A STRUCTURE OF HIGH-AFFINITY HUMAN PD-1/PD-L2 COMPLEX
#35Methods and compositions for decreasing soluble immune receptor CD28
#36METHODS AND KITS FOR EVALUATING CLINICAL OUTCOMES OF AUTOIMMUNE DISEASE
#37MOLECULAR PROFILING FOR CANCER
#38Method of scoring a sample comprising tumor tissue
#39USE OF PD-1 AND TIM-3 AS A MEASURE FOR CD8+ CELLS IN PREDICTING AND TREATING RENAL CELL CARCINOMA
#40CD8 T cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery
#41METHOD FOR DETERMINING THE POTENTIAL EFFICACY OF ANTICANCER TREATMENT
#42Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
#43METHODS OF DIAGNOSING AND TREATING LUPUS
#44Method of scoring a sample comprising tumor tissue
#45MUTEINS OF TEAR LIPOCALIN AND METHODS FOR OBTAINING THE SAME
#46Immune checkpoint molecular fitness profiling by mass spectrometry
#47PROGRAMMED CELL DEATH (PD-1) INHIBITOR THERAPY FOR PATIENTS WITH PD-1-EXPRESSING CANCERS
#48Methods and compositions for obtaining a tuberculosis assessment in a subject
#49Combination therapy for hepatocellular carcinoma
#50Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
#51ANTI-H7CR ANTIBODIES
#52Methods of determining patient populations amenable to immunomodulatory treatment of cancer
#53ANTI-H7CR ANTIBODIES
#54MOLECULAR PROFILING FOR CANCER
#55COMMON CAPTURE CELL SEPARATIONS DONE VIA SIMULTANEOUS INCUBATION OF COMPONENTS
#56Compositions and methods for expressing polypeptides on the surface of cells
#57Anti-PD-1 antibodies
#58TH17-PRONE CD146+CCR5+ T-CELL POPULATION AS AN EARLY MARKER OF INTESTINAL GRAFT-VERSUS-HOST DISEASE
#59Biomarker And Therapy Intervention For Malignancy Risk Patients
#60Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
#61Muteins of tear lipocalin and methods for obtaining the same
#62Anti-H7CR antibodies
#63CD28 expression during lenalidomide immune modulation
#64CANCER PROGNOSTIC ASSAYS
#65Muteins of human lipocalin 2 with affinity for CTLA-4
#66Muteins of tear lipocalin and methods for obtaining the same
#67Method of assaying an individual for immune impairment
#68Cellular COPD Diagnosis
#69Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist
#70Muteins of tear lipocalin and methods for obtaining the same
#71Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes
#72Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease
#73Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
#74Systems and methods for measuring changes in cellular activity in live tissue
#75Methods related to a structure of high-affinity human PD-1/PD-L2 complex